Synthetic Multivalent Tn Antigen Elicits Valency-Dependent IgG Antibody Production

Area of Science:

• Immunology
• Biotechnology
• Cancer Research

Background:

• The Tn antigen is a promising target for developing effective cancer vaccines.
• Developing multivalent Tn antigens is crucial for enhancing immune responses.

Purpose of the Study:

• To evaluate the efficacy of dendrimer-based multivalent Tn antigens in generating antibody responses.
• To assess the subtype-specific antibody generation and cancer cell targeting capabilities.

Main Methods:

• Utilized poly(ether imine) (PETIM) dendrimers (generations 1, 2, and 3) to create tetra-, octa-, and hexadecavalent Tn antigens.
• Assessed antibody production in mice via ELISA after periodic immunization.
• Evaluated antibody binding specificity to cancer cells (MCF-7, Jurkat) and noncancerous cells (HEK293).

Main Results:

• All multivalent Tn antigens demonstrated significantly stronger IgG antibody responses compared to Tn-BSA conjugate.
• The third-generation glycoconjugate induced the highest antibody titers (1:204800 dilution).
• Generated antibodies showed strong and selective binding to MCF-7 and Jurkat cancer cells, with no binding to HEK293 cells.

Conclusions:

• Dendrimer-based multivalent Tn antigens are well-tolerated and elicit potent, subtype-specific antibody generation.
• Higher antigen valency correlates with increased antibody production efficacy and specificity.
• These findings support the potential of multivalent Tn antigens as cancer vaccine candidates.